We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-5.35%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.19B
AUM Growth
+$165M
Cap. Flow
+$307M
Cap. Flow %
25.82%
Top 10 Hldgs %
50.1%
Holding
72
New
19
Increased
15
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$40.2M
2
VERV
Verve Therapeutics
VERV
+$31.5M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$29.2M
4
LENZ
LENZ Therapeutics
LENZ
+$26.6M
5
IPSC icon
Century Therapeutics
IPSC
+$25.1M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$21.6M
2
RPTX
Repare Therapeutics
RPTX
+$18.7M
3
BTAI icon
BioXcel Therapeutics
BTAI
+$17.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$10.1M
5
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$9.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
26
LeonaBio Inc
LONA
$65.9M
$14.4M 1.21%
141,081
+40,000
+40% +$6.98M
JANX icon
27
Janux Therapeutics
JANX
$959M
$13.7M 1.15%
+547,122
New +$12.2M
KZR
28
DELISTED
Kezar Life Sciences
KZR
$12.5M 1.05%
230,000
+150,000
+188% +$8.52M
RAIN
29
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$12.1M 1.02%
+780,331
New +$13.7M
ACRS icon
30
Aclaris Therapeutics
ACRS
$758M
$11.9M 1%
+675,000
New +$15.3M
COGT icon
31
Cogent Biosciences
COGT
$6.98B
$11.5M 0.97%
1,420,500
– –
PRLD icon
32
Prelude Therapeutics
PRLD
$315M
$11.5M 0.96%
+400,000
New +$14.2M
KNSA icon
33
Kiniksa Pharmaceuticals
KNSA
$4.95B
$11.1M 0.94%
800,000
+400,000
+100% +$6.08M
HARP
34
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$11.1M 0.93%
80,000
+50,000
+167% +$9.54M
ELDN icon
35
Eledon Pharmaceuticals
ELDN
$278M
$10.6M 0.89%
1,339,793
+1,115,722
+498% +$10.5M
LABP
36
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$10.4M 0.87%
89,911
+16,511
+22% +$1.84M
RPTX
37
DELISTED
Repare Therapeutics
RPTX
$10.3M 0.86%
330,000
-570,000
-63% -$18.7M
RAPT
38
DELISTED
RAPT Therapeutics
RAPT
$8.58M 0.72%
+33,750
New +$6.31M
TRML
39
DELISTED
Tourmaline Bio
TRML
$7.46M 0.63%
+50,792
New +$7.78M
CGEM icon
40
Cullinan Oncology
CGEM
$1.09B
$7.43M 0.62%
288,458
-125,000
-30% -$3.84M
PMVP icon
41
PMV Pharmaceuticals
PMVP
$62.9M
$7.06M 0.59%
206,564
+6,564
+3% +$219K
GLUE icon
42
Monte Rosa Therapeutics
GLUE
$1.94B
$6.81M 0.57%
+300,000
New +$6.11M
ATXS
43
DELISTED
Astria Therapeutics
ATXS
$6.73M 0.57%
+531,667
New +$6.9M
ASLN
44
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$6.6M 0.55%
50,000
-7,500
-13% -$938K
ALGS icon
45
Aligos Therapeutics
ALGS
$25.9M
$4.34M 0.36%
8,511
-10,551
-55% -$6.73M
CCCC icon
46
C4 Therapeutics
CCCC
$400M
$4.27M 0.36%
112,928
– –
IMA
47
ImageneBio Inc
IMA
$64.3M
$4.21M 0.35%
24,988
-10,000
-29% -$2.21M
ANNX icon
48
Annexon
ANNX
$873M
$3.59M 0.3%
159,622
– –
TNGX icon
49
Tango Therapeutics
TNGX
$4.4B
$2.28M 0.19%
200,000
– –
ARYD
50
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.14M 0.18%
200,000
– –
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2021 Portfolio in Review

As of Q2 2021, Logos Global Management held 72 positions worth $1.19B, up 16% from $1.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Logos Global Management deployed $307M of net new capital in Q2 2021, opening 19 new positions and adding to 15 existing holdings. Its largest new stake was Verve Therapeutics: 758,265 shares worth $45.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $21.6M trimmed.

  • Logos Global Management's largest Q2 2021 buy was Verve Therapeutics: 758,265 shares worth $45.7M.
  • Logos Global Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $40.2M increase.
  • Logos Global Management's biggest Q2 2021 reduction was Dyne Therapeutics, cutting an estimated $21.6M.
  • Logos Global Management fully exited BioXcel Therapeutics in Q2 2021, selling an estimated $17.3M.
  • Logos Global Management's ten largest holdings make up 50% of its $1.19B portfolio in Q2 2021.
  • Logos Global Management opened 19 new positions and closed 14 in Q2 2021.
  • Logos Global Management's portfolio value rose 16% quarter-over-quarter to $1.19B.

Based on Logos Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.